Abstract:Breast cancer can be classified into several types. Among them, triple-negative breast cancer (TNBC) is breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Since targeted therapy for breast cancer relies on the three receptors, treatment outcomes have been worst in TNBCs. However, clinical benefit of immune-checkpoint inhibitors (ICIs) with chemotherapy over chemotherapy alone was demonstrated in the KEYNOTE-355 and IMPASSION-130 trials in terms of overall survival, opening new avenue for patients with metastatic PD-L1+ TNBC. After several studies with ICIs, researchers found that the tumor microenvironment affects the response rate of immunotherapies. Therefore, to unravel the heterogeneity of tumor microenvironment of TNBC patients, we collected 28 TNBC samples from 6 public single cell RNA sequencing breast cancer studies. Results: From 124,301 cells populating tumors and tumor-microenvironment (TMEs), we first identified epithelial cells separately. Using epithelial cells alone, we identified the Baylor-proposed TNBC molecular subtype of each patient. This approach with epithelial cells revealed that 3 basal-like immune-activated (BLIA), 11 basal-like immune-suppressed (BLIS), 5 luminal- androgen receptor (LAR), and 9 unclassified subtypes. By comparing cell number and cell-cell interactions, the heterogeneity of TME-consisting cell populations between the TNBC subtypes was analyzed. Analysis of tumor-infiltrating lymphocytes revealed their difference in activation, expansion, and exhaustion programs across patients. Among the subtypes, the LAR subtype had less amount of exhausted CD8+ T cells and regulatory T cells. This finding was consistent with cell-cell interaction analysis. In the case of the LAR subtype, the interaction between regulatory T cells and CD8 T cells was less active than other subtypes. Also, the interaction between cytotoxic cells (T cells and NK cells) and regulatory T cells was less active in the LAR subtype. Additionally, tumor cells in the LAR subtype seem to inhibit cytotoxic cells to a lesser extent. When we repeated our analyses using whole cells including epithelial and immune-stromal cells, the molecular subtypes of each subject were changed (7 of 19, 36.8%). 4 of 11 BLIS were changed to BLIA, 1 of 11 BLIS were changed to mesenchymal (MES), and 2 of 5 LAR were changed to MES. Characteristics of immune cells in the epithelial-based LAR subtype were conserved in the whole cells-based MES. Conclusions:This extensive meta-analysis of public single cell RNA sequencing analysis enhances our knowledge about the heterogeneity and dynamics of the tumor microenvironment. These results offer insights about potential diagnostic and therapeutic targets for TNBC depending on their subtypes. Citation Format: Kyungsoo Kim, Sung Gwe Ahn, Soong June Bae, Chihhao Chu, Jung Hwan Ji, Jee Hung Kim, Joon Jeong. Unraveling heterogeneity of tumor microenvironment of TNBC patients by meta-analysis of 6 breast cancer scRNAseq studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2542.

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC

Cancer‐associated Fibroblasts in Breast Cancer: Challenges and Opportunities

Revealing Cellular Heterogeneity and Key Regulatory Factors of Triple-Negative Breast Cancer through Single-Cell RNA Sequencing

Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC

Bioinformatic analysis of single-cell RNA sequencing dataset dissects cellular heterogeneity of triple-negative breast cancer in transcriptional profile, splicing event and crosstalk network

Landscape of Cancer-Associated Fibroblasts Identifies the Secreted Biglycan As a Protumor and Immunosuppressive Factor in Triple-Negative Breast Cancer.

scRNA-seq characterizing the heterogeneity of fibroblasts in breast cancer reveals a novel subtype SFRP4+ CAF that inhibits migration and predicts prognosis

Single-cell RNA-seq data reveals TNBC tumor heterogeneity through characterizing subclone compositions and proportions

Abstract 2542: Unraveling heterogeneity of tumor microenvironment of TNBC patients by meta-analysis of 6 breast cancer scRNAseq studies

Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct cancer-associated fibroblasts in head and neck squamous cell carcinoma

Pan-Cancer Single-Cell Analysis Revealing the Heterogeneity of Cancer-Associated Fibroblasts in Skin Tumors

Establishment of a tumor-associated fibroblast associated gene score based on scRNA-seq to predict prognosis in patients with triple-negative breast cancer

Single-cell Atlas Reveals a Distinct Immune Profile Fostered by T Cell-B Cell Crosstalk in Triple Negative Breast Cancer

Abstract B046: Analyzing heterogeneity of tumor microenvironment of TNBC patients by meta-analysis of 7 breast cancer scRNAseq studies

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer

Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing

Single-cell and Bulk RNA Sequencing Analysis of B Cell Marker Genes in TNBC TME Landscape and Immunotherapy

Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment

Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer

Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer